Sinphar Pharmaceutical Co Ltd - Asset Resilience Ratio
Sinphar Pharmaceutical Co Ltd (1734) has an Asset Resilience Ratio of 1.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Sinphar Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check 1734 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sinphar Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sinphar Pharmaceutical Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$115.89 Million | 1.8% |
| Total Liquid Assets | NT$115.89 Million | 1.80% |
Asset Resilience Insights
- Limited Liquidity: Sinphar Pharmaceutical Co Ltd maintains only 1.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sinphar Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sinphar Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690 |
Biotechnology | 0.31% |
|
ORUM
KQ:475830 |
Biotechnology | 82.74% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
TG Therapeutics Inc
NASDAQ:TGTX |
Biotechnology | 4.72% |
|
Green Cross Holdings Preference Shares
KO:005257 |
Biotechnology | 0.50% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Cybin Inc
NEO:CYBN |
Biotechnology | 0.21% |
Annual Asset Resilience Ratio for Sinphar Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Sinphar Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.12% | NT$130.49 Million ≈ $4.11 Million |
NT$6.15 Billion ≈ $193.85 Million |
+0.50pp |
| 2024-12-31 | 1.63% | NT$102.36 Million ≈ $3.23 Million |
NT$6.30 Billion ≈ $198.43 Million |
+1.52pp |
| 2023-12-31 | 0.11% | NT$6.66 Million ≈ $209.83K |
NT$6.25 Billion ≈ $196.94 Million |
0.00pp |
| 2022-12-31 | 0.11% | NT$6.66 Million ≈ $209.83K |
NT$6.19 Billion ≈ $194.87 Million |
-0.70pp |
| 2021-12-31 | 0.81% | NT$50.10 Million ≈ $1.58 Million |
NT$6.22 Billion ≈ $195.99 Million |
-0.02pp |
| 2020-12-31 | 0.82% | NT$50.43 Million ≈ $1.59 Million |
NT$6.13 Billion ≈ $193.03 Million |
+0.06pp |
| 2019-12-31 | 0.77% | NT$45.41 Million ≈ $1.43 Million |
NT$5.92 Billion ≈ $186.40 Million |
+0.48pp |
| 2018-12-31 | 0.28% | NT$16.62 Million ≈ $523.50K |
NT$5.88 Billion ≈ $185.19 Million |
-1.28pp |
| 2017-12-31 | 1.56% | NT$94.31 Million ≈ $2.97 Million |
NT$6.04 Billion ≈ $190.39 Million |
+0.83pp |
| 2016-12-31 | 0.73% | NT$45.21 Million ≈ $1.42 Million |
NT$6.21 Billion ≈ $195.54 Million |
-0.94pp |
| 2015-12-31 | 1.67% | NT$106.53 Million ≈ $3.36 Million |
NT$6.39 Billion ≈ $201.21 Million |
+0.68pp |
| 2014-12-31 | 0.99% | NT$63.70 Million ≈ $2.01 Million |
NT$6.46 Billion ≈ $203.65 Million |
-1.44pp |
| 2013-12-31 | 2.42% | NT$138.06 Million ≈ $4.35 Million |
NT$5.70 Billion ≈ $179.69 Million |
+0.49pp |
| 2012-12-31 | 1.93% | NT$87.42 Million ≈ $2.75 Million |
NT$4.54 Billion ≈ $142.90 Million |
+0.44pp |
| 2011-12-31 | 1.49% | NT$69.04 Million ≈ $2.18 Million |
NT$4.64 Billion ≈ $146.14 Million |
+1.08pp |
| 2010-12-31 | 0.40% | NT$14.99 Million ≈ $472.24K |
NT$3.71 Billion ≈ $116.99 Million |
-1.62pp |
| 2009-12-31 | 2.02% | NT$72.46 Million ≈ $2.28 Million |
NT$3.58 Billion ≈ $112.93 Million |
-10.36pp |
| 2008-12-31 | 12.38% | NT$444.77 Million ≈ $14.01 Million |
NT$3.59 Billion ≈ $113.20 Million |
+11.59pp |
| 2007-12-31 | 0.79% | NT$25.09 Million ≈ $790.54K |
NT$3.16 Billion ≈ $99.70 Million |
-0.35pp |
| 2006-12-31 | 1.14% | NT$31.69 Million ≈ $998.38K |
NT$2.77 Billion ≈ $87.42 Million |
-0.34pp |
| 2005-12-31 | 1.48% | NT$42.03 Million ≈ $1.32 Million |
NT$2.84 Billion ≈ $89.45 Million |
+0.02pp |
| 2004-12-31 | 1.46% | NT$34.23 Million ≈ $1.08 Million |
NT$2.35 Billion ≈ $73.93 Million |
+0.62pp |
| 2003-12-31 | 0.84% | NT$17.37 Million ≈ $547.38K |
NT$2.06 Billion ≈ $64.92 Million |
-- |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more